NZ596747A - Crystalline form of pemirolast - Google Patents
Crystalline form of pemirolastInfo
- Publication number
- NZ596747A NZ596747A NZ596747A NZ59674710A NZ596747A NZ 596747 A NZ596747 A NZ 596747A NZ 596747 A NZ596747 A NZ 596747A NZ 59674710 A NZ59674710 A NZ 59674710A NZ 596747 A NZ596747 A NZ 596747A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pemirolast
- disease
- inflammatory disorder
- atherosclerosis
- instability
- Prior art date
Links
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004439 pemirolast Drugs 0.000 title abstract 6
- 208000027866 inflammatory disease Diseases 0.000 abstract 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Secondary Cells (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18735509P | 2009-06-16 | 2009-06-16 | |
| US18734809P | 2009-06-16 | 2009-06-16 | |
| PCT/GB2010/001168 WO2010146348A2 (en) | 2009-06-16 | 2010-06-15 | New crystalline form of pemirolast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596747A true NZ596747A (en) | 2014-01-31 |
Family
ID=43264726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596747A NZ596747A (en) | 2009-06-16 | 2010-06-15 | Crystalline form of pemirolast |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20120157415A1 (enExample) |
| EP (2) | EP3141549A1 (enExample) |
| JP (2) | JP5722317B2 (enExample) |
| KR (2) | KR20170049645A (enExample) |
| CN (1) | CN102596202B (enExample) |
| AR (1) | AR077915A1 (enExample) |
| AU (1) | AU2010261540B2 (enExample) |
| BR (1) | BRPI1015559A2 (enExample) |
| CA (1) | CA2765408A1 (enExample) |
| CY (1) | CY1118413T1 (enExample) |
| DK (1) | DK2443120T3 (enExample) |
| EA (1) | EA025865B1 (enExample) |
| ES (1) | ES2613059T3 (enExample) |
| HR (1) | HRP20170023T1 (enExample) |
| HU (1) | HUE032978T2 (enExample) |
| IL (1) | IL216670A (enExample) |
| LT (1) | LT2443120T (enExample) |
| ME (1) | ME02685B (enExample) |
| MX (1) | MX2011013676A (enExample) |
| NZ (1) | NZ596747A (enExample) |
| PL (1) | PL2443120T3 (enExample) |
| PT (1) | PT2443120T (enExample) |
| RS (1) | RS55558B1 (enExample) |
| SA (1) | SA114350792B1 (enExample) |
| SG (1) | SG176295A1 (enExample) |
| SI (1) | SI2443120T1 (enExample) |
| SM (2) | SMT201700085T1 (enExample) |
| TW (1) | TWI504599B (enExample) |
| UY (1) | UY32711A (enExample) |
| WO (2) | WO2010146341A2 (enExample) |
| ZA (1) | ZA201109045B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012005513A (es) * | 2009-11-13 | 2012-06-19 | Cardoz Ab | Pemirolast para el tratamiento de inflamacion sistemica de bajo grado. |
| EA034550B1 (ru) * | 2013-03-09 | 2020-02-19 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способы лечения, снижения частоты и/или профилактики ишемических событий |
| WO2016063085A1 (en) | 2014-10-23 | 2016-04-28 | Rspr Pharma Ab | Use of pemirolast in the treatment of acute asthma |
| WO2016102941A1 (en) | 2014-12-22 | 2016-06-30 | Rspr Pharma Ab | New combination of pemirolast and montelukast |
| GB201518831D0 (en) | 2015-10-23 | 2015-12-09 | Rspr Pharma Ab | New use |
| CN110267661B (zh) * | 2016-10-03 | 2021-08-03 | 布利本迅药业(上海)有限公司 | 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JP2504788B2 (ja) | 1987-11-10 | 1996-06-05 | 東京田辺製薬株式会社 | ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤 |
| JP2837449B2 (ja) * | 1989-08-11 | 1998-12-16 | 東京田辺製薬株式会社 | ピリド［１，２―ａ］ピリミジン誘導体の製造法 |
| ITMI20011764A1 (it) | 2001-08-10 | 2003-02-10 | Dinamite Dipharma Spa | Metodo per l'ottenimento del pemirolast ad elevata purezza |
| HUE029336T2 (en) | 2005-09-16 | 2017-02-28 | Daiichi Sankyo Co Ltd | For the preparation of an optically active diamine derivative and process |
| CN101610765A (zh) * | 2006-12-18 | 2009-12-23 | 卡多兹公司 | 用于治疗炎症的新组合物 |
| EP2107907B1 (en) * | 2006-12-20 | 2012-02-01 | Cardoz AB | Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders |
-
2010
- 2010-06-15 SG SG2011088655A patent/SG176295A1/en unknown
- 2010-06-15 CN CN201080026883.3A patent/CN102596202B/zh not_active Expired - Fee Related
- 2010-06-15 SI SI201031380A patent/SI2443120T1/sl unknown
- 2010-06-15 SM SM20170085T patent/SMT201700085T1/it unknown
- 2010-06-15 EA EA201200017A patent/EA025865B1/ru not_active IP Right Cessation
- 2010-06-15 ES ES10732402.2T patent/ES2613059T3/es active Active
- 2010-06-15 MX MX2011013676A patent/MX2011013676A/es active IP Right Grant
- 2010-06-15 EP EP16194237.0A patent/EP3141549A1/en not_active Withdrawn
- 2010-06-15 PL PL10732402T patent/PL2443120T3/pl unknown
- 2010-06-15 BR BRPI1015559A patent/BRPI1015559A2/pt not_active IP Right Cessation
- 2010-06-15 EP EP10732402.2A patent/EP2443120B1/en active Active
- 2010-06-15 ME MEP-2017-8A patent/ME02685B/me unknown
- 2010-06-15 CA CA2765408A patent/CA2765408A1/en not_active Abandoned
- 2010-06-15 UY UY0001032711A patent/UY32711A/es not_active Application Discontinuation
- 2010-06-15 PT PT107324022T patent/PT2443120T/pt unknown
- 2010-06-15 JP JP2012515552A patent/JP5722317B2/ja not_active Expired - Fee Related
- 2010-06-15 AU AU2010261540A patent/AU2010261540B2/en not_active Ceased
- 2010-06-15 RS RS20170003A patent/RS55558B1/sr unknown
- 2010-06-15 KR KR1020177012036A patent/KR20170049645A/ko not_active Ceased
- 2010-06-15 HR HRP20170023TT patent/HRP20170023T1/hr unknown
- 2010-06-15 HU HUE10732402A patent/HUE032978T2/hu unknown
- 2010-06-15 DK DK10732402.2T patent/DK2443120T3/en active
- 2010-06-15 KR KR1020127001227A patent/KR20120032530A/ko not_active Ceased
- 2010-06-15 LT LTEP10732402.2T patent/LT2443120T/lt unknown
- 2010-06-15 US US13/378,787 patent/US20120157415A1/en not_active Abandoned
- 2010-06-15 TW TW099119396A patent/TWI504599B/zh not_active IP Right Cessation
- 2010-06-15 NZ NZ596747A patent/NZ596747A/en not_active IP Right Cessation
- 2010-06-15 WO PCT/GB2010/001159 patent/WO2010146341A2/en not_active Ceased
- 2010-06-15 WO PCT/GB2010/001168 patent/WO2010146348A2/en not_active Ceased
- 2010-06-16 SA SA114350792A patent/SA114350792B1/ar unknown
- 2010-06-16 AR ARP100102136A patent/AR077915A1/es unknown
-
2011
- 2011-11-29 IL IL216670A patent/IL216670A/en not_active IP Right Cessation
- 2011-12-08 ZA ZA2011/09045A patent/ZA201109045B/en unknown
-
2014
- 2014-05-12 US US14/274,951 patent/US9006431B2/en not_active Expired - Fee Related
-
2015
- 2015-03-24 JP JP2015060587A patent/JP2015120750A/ja active Pending
-
2016
- 2016-12-28 US US15/392,497 patent/US20170202839A1/en not_active Abandoned
-
2017
- 2017-01-11 CY CY20171100039T patent/CY1118413T1/el unknown
- 2017-02-08 SM SM201700085T patent/SMT201700085B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596747A (en) | Crystalline form of pemirolast | |
| CY1122628T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
| CA2822311C (en) | Detachable metal balloon delivery device and method | |
| MX2013010076A (es) | Composiciones y metodos que comprenden c16:1n7 palmitoleato. | |
| DE602007008042D1 (de) | Waschdesinfektor mit Bad, an das die Ablage mit daran befestigtem Endoskop abnehmbar geladen ist | |
| DE602008005497D1 (de) | Schäumbare Zusammensetzung, die im Wesentlichen frei von pharmazeutisch aktiven Inhaltsstoffen ist, zur Behandlung der menschlichen Haut | |
| WO2011143360A8 (en) | Compositions, methods and systems for the synthesis and use of imaging agents | |
| MX2012001671A (es) | Metodos, compuestos y composiciones para la administracion de acido 1,3-propanedisulfonico. | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| TN2011000370A1 (en) | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof | |
| CU24439B1 (es) | Preparación de gadobutrol de alta pureza | |
| Bellien et al. | Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? | |
| EP4410833A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| MX2010006650A (es) | Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica. | |
| MX2009013937A (es) | Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. | |
| RU2008138358A (ru) | Композиция с фиксированной дозой фитата и цинка | |
| MX2009006692A (es) | Derivados de prostaciclina. | |
| PL2247573T3 (pl) | Sole kwasu węglowego i siarkowego estrów 3-(2,2,2-trimetylohydrazynio)propionianów, oraz ich zastosowanie do wytwarzania dihydratu 3-(2,2,2-trimetylohydrazynio)propionianu | |
| TW200628451A (en) | Novel pyrimidine derivatives and their use | |
| SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
| MX2019015712A (es) | Formas cristalinas de beta-sitosterol. | |
| NZ609804A (en) | Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | |
| MX2012006217A (es) | Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne. | |
| UA37749U (uk) | Композиційний блокатор окислення арахідонової кислоти | |
| 郭建明 | Surgical treatment of visceral artery aneurysms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: CARDOZ AB, SE Free format text: OLD OWNER(S): ULRIKA ROSENSTROM; CARDOZ AB; KAROL HORVATH |
|
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: CORRECTION TO TITLE (54) |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUN 2017 BY CPA GLOBAL Effective date: 20140501 |
|
| LAPS | Patent lapsed |